Navigation Links
Cumberland Pharmaceuticals Announces Appointments
Date:12/18/2007

NASHVILLE, Tenn., Dec. 18 /PRNewswire/ -- Cumberland Pharmaceuticals is pleased to announce the appointment of two senior executives.

David L. Lowrance has been promoted to Vice President and Chief Financial Officer. In this role, he is responsible for overseeing the company's accounting and financial activities, including financial reporting and planning. Mr. Lowrance has 17 years of financial and accounting experience, joining Cumberland in 2003 as Director of Finance and Accounting. He spent eight years with two global conglomerates, including four years as senior vice president for Icore International. Prior to this, Mr. Lowrance spent four years at Ernst & Young, LLP. A graduate of the University of Georgia, he is a certified public accountant.

Doug Jack has joined the company as Senior Manager of SEC Reporting. He is responsible for the preparation of all SEC-required financial reports. Mr. Jack brings more than 14 years of accounting and financial experience to his position. Prior to joining Cumberland, he spent eight years as audit manager with Ernst & Young and PricewaterhouseCoopers, and served as CFO and controller at Southern Specialty Brands. A certified public accountant, he is a graduate of the University of Georgia.

"We are fortunate to work with these outstanding individuals who bring great depth of experience and knowledge in their respective areas," said A.J. Kazimi, Cumberland's Chief Executive Officer. "Each will play an important role in taking the company to the next level as we continue to grow and capitalize on opportunities created by the shifting pharmaceutical landscape."

About Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. Cumberland's primary target markets include hospital acute care and gastroenterology. Cumberland markets Acetadote(R) for the treatment of acetaminophen poisoning and Kristalose(R), a prescription strength laxative. The Company is also developing Amelior(R) which is in Phase III studies for the treatment of both pain and fever. Cumberland is dedicated to providing innovative products which improve quality of care for patients.


'/>"/>
SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Orion ICG, LLC Announces Acquisition of Cumberland Therapy Services, Inc.
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... Gym Source, ... of a new showroom at South Dixie Hwy in Miami, FL. , “We are ... Gym Source. “The new innovative in-store concept is designed to give clients a seamless ...
(Date:1/17/2017)... Los Angeles, CA (PRWEB) , ... January 17, ... ... conflicted and concerned by the political/social/economic events, Dr. Carol Francis re-releases powerfully uplifting ... tragedies and magical moments that help everyone endure and pass through tough times, ...
(Date:1/17/2017)... ... January 17, 2017 , ... Kevin Harrington (one of the original Sharks ... DRTV campaigns regarding the topic of Beauty and Personal Care. , ... What better way to commit to these changes than beginning with personal care and ...
(Date:1/17/2017)... ... January 17, 2017 , ... Achieve TMS West, with multiple ... new office in San Clemente, California this month. Achieve TMS West is the ... treating individuals struggling with major depression. Depression impacts over 15 million adults in ...
(Date:1/17/2017)... ... January 17, 2017 , ... Peoples Health is pleased to ... on Dec. 1, 2016. Peoples Health, a Metairie-based Medicare Advantage company, serves more ... addition to our provider network, and the addition will benefit our members in ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... -- Research and Markets has announced the addition of ... to their offering. ... The global fluoropolymer market in the healthcare industry to grow ... Global Fluoropolymer Market in the Healthcare Industry 2016-2020, has been ... experts. The report covers the market landscape and its growth prospects ...
(Date:1/17/2017)... Tocagen Inc ., a clinical-stage, cancer-selective gene therapy company, today announced ... pharmaceutical development at Tocagen, will present at Phacilitate Cell & ... Miami . Details of the ... ... - what to do when and why Date and Time: Wednesday, ...
(Date:1/17/2017)... 2017 Research and Markets has announced the ... Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormone) Drug ... 2021" report to their offering. ... The global active pharmaceutical ingredients market is ... Billion in 2016, growing at a CAGR of 6.3% from 2016 ...
Breaking Medicine Technology: